Efficacy of BodyMirror Clinical MS Multimodal Game-Based Digital Therapeutic for Remote Monitoring and Neurorehabilitation in Multiple Sclerosis: Protocol for a Multisite Randomised Controlled Trial

This paper outlines the protocol for a prospective, multisite, randomized controlled trial designed to evaluate the efficacy of the BodyMirror Clinical MS platform—a multimodal digital therapeutic combining wearable biosensors and game-based neurorehabilitation—in remotely monitoring disease progression and delivering personalized treatment for 300 individuals with multiple sclerosis over a 24-month period.

The Gist

Imagine you have a car that is slowly developing a problem. Usually, you only find out about the problem when you take it to the mechanic once a year for a big check-up. By then, the engine might already be damaged, and the mechanic can only guess what happened between visits.

This paper is about a new, high-tech "dashboard" for people with Multiple Sclerosis (MS) that lets them monitor their car's engine every single day from the comfort of their own garage.

Here is the breakdown of the BodyMirror Clinical MS™ trial, explained simply:

1. The Problem: The "Blind Spot" in MS Care

Multiple Sclerosis is a disease where the body's immune system attacks the protective coating of the nerves. It's tricky because:

• It's invisible: Sometimes the disease gets worse even when the patient feels fine (called "silent progression").
• The check-ups are rare: Doctors usually rely on MRI scans (expensive, hospital-based photos of the brain) and walking tests done once or twice a year.
• The gap: Between those yearly visits, the disease might be changing, but no one knows until it's too late.

2. The Solution: A "Fitness Tracker" for the Brain

The researchers (from a company called MyelinZ) have built a system called BodyMirror. Think of it as a super-advanced fitness tracker, but instead of counting steps, it measures how well your brain and body are talking to each other.

How it works:

• The Gear: You wear a comfortable headband (like a sweatband) that reads brain waves (EEG) and a belt that reads muscle signals (EMG) and movement.
• The Game: Instead of staring at a boring medical chart, you play video games on your phone or tablet. These aren't just "fun" games; they are designed by neuroscientists to test your memory, balance, speech, and reaction time.
• The Magic: As you play, the system records how your brain and muscles are working. It uses Artificial Intelligence (AI) to spot tiny changes that a human doctor might miss.

3. The Big Experiment (The Trial)

To prove this works, they are launching a massive 2-year experiment involving 400 people:

• 300 people with MS: They are split into two teams.
  • Team A (The Rehab Team): They play games that get harder as they get better. The AI adjusts the difficulty to train their specific weak spots (like memory or walking).
  • Team B (The Control Team): They play games that look and feel exactly the same, but the AI doesn't adjust the difficulty. They are just playing for fun, not for therapy. This helps the researchers know if the training is actually working or if it's just the act of playing games.
• 100 Healthy People: They play the games too to create a "perfect score" baseline, so the researchers know what "normal" looks like.

The Goal:
The main question is: Does the team playing the "smart" training games stay healthier and slower to decline than the team just playing for fun?

4. Why This is a Game-Changer

• From "Snapshot" to "Movie": Current medicine takes a snapshot of your health once a year. This system records a 24-hour movie of your health every day.
• Early Warning System: Just like a smoke detector goes off before the fire spreads, this system hopes to detect "silent" disease progression before it causes permanent damage.
• Personalized Training: If the system notices your left hand is getting slower, it will automatically give you more games to train your left hand. It's like having a personal trainer who knows exactly what you need, 24/7.
• Privacy First: They are using a special technology called "Federated Learning." Imagine everyone solving a puzzle in their own house, and only the answers are sent to the central office, not the puzzle pieces themselves. This means your private medical data stays on your device and never leaves your home.

5. The Bottom Line

If this trial is successful, it could change how we treat MS forever. Instead of waiting for a patient to get worse and then reacting, doctors could use this "digital mirror" to see problems coming early and adjust treatment immediately.

In short: It's turning the scary, invisible progression of MS into something you can see, measure, and train against, right from your living room.

Technical Summary

Based on the provided protocol document, here is a detailed technical summary of the BodyMirror Clinical MS™ trial.

1. Problem Statement

Multiple Sclerosis (MS) is a chronic, heterogeneous neurodegenerative disease characterized by progressive disability and "silent" disease progression that often goes undetected by standard clinical methods.

• Limitations of Current Care: Standard monitoring relies on episodic neurological assessments (e.g., EDSS scores) and Magnetic Resonance Imaging (MRI). These methods are often:
  • Insensitive: They fail to detect subtle, continuous functional changes or "silent progression" between visits.
  • Subjective: Clinical scores like EDSS rely on visual inspection and can be inconsistent.
  • Resource-Intensive: Frequent hospital visits and MRIs are costly and burdensome for patients.
  • Reactive: They often detect decline only after significant damage has occurred, rather than predicting relapses or early progression.
• Rehabilitation Gap: There is a lack of engaging, personalized, and remote neurorehabilitation tools that can continuously adapt to a patient's changing condition to promote neuroplasticity.

2. Methodology

The study is a prospective, randomized, double-blind, parallel-group, multisite clinical trial (R-MMS Trial) designed to validate a novel Software-as-a-Medical-Device (SaMD).

A. Study Design & Population

• Duration: 24 months of treatment/monitoring (Total study duration: 30 months).
• Sample Size: 400 participants total.
  • 300 MS Patients: Stratified into Relapsing-Remitting MS (RRMS) and Secondary Progressive MS (SPMS).
  • 100 Healthy Controls: Age-matched to establish normative data.
• Randomization: MS patients are randomized 1:1 into:
  1. Intervention Group (n=150): Receives adaptive, AI-driven neurorehabilitation games.
  2. Control Group (n=150): Receives non-therapeutic digital activities (matched for engagement, duration, and visual design but lacking adaptive therapeutic algorithms).
• Blinding: Double-blind design where participants, outcome assessors, and data analysts are unaware of group allocation.

B. The BodyMirror System (SaMD)

The platform integrates multimodal biosensors, neuroscience-based gaming, and machine learning:

• Hardware Sensors:
  • EEG Headband: 4-channel, dry-electrode, gel-free (O1, O2, T3, T4) at 256 Hz sampling.
  • EMG/IMU Band: 1-channel EMG (1000 Hz) and 6-axis Inertial Measurement Unit (95 Hz) for muscle and motion tracking.
• Software & AI:
  • Game Suite: 16–20 neurogames targeting cognitive (memory, attention), motor (dexterity, gait), and speech functions.
  • Adaptive Engine: AI algorithms analyze real-time biosignals and game performance to adjust difficulty and prescribe personalized rehabilitation plans.
  • Digital Biomarkers: The system extracts digital biomarkers from EEG (brain activity), EMG (muscle fatigue), IMU (gait/balance), speech patterns, and behavioral metrics.
• Privacy Architecture: Utilizes Federated Learning (FL) combined with Privacy-Enhancing Technologies (PETs) like Homomorphic Encryption. Data is processed locally on the device/hospital server; only model parameters are aggregated, ensuring GDPR/HIPAA compliance without raw data leaving the local node.

C. Intervention Protocol

• Frequency: 3 sessions per week, 30 minutes each, for 24 months.
• Baseline: A 4-week non-adaptive baseline period to establish individual performance baselines before randomization.
• Assessments:
  • Primary Endpoint: Change in Expanded Disability Status Scale (EDSS) from baseline to Month 24.
  • Secondary Endpoints: Changes in Multiple Sclerosis Functional Composite (MSFC), MRI brain volume, cognitive scores (SDMT, PASAT), patient-reported outcomes (quality of life, fatigue), and adherence.
  • Imaging: MRI scans at baseline, 12, and 24 months.

3. Key Contributions

• First Large-Scale Multimodal SaMD Trial: This is the first large-scale (n=400) randomized controlled trial evaluating a system that combines wearable biosensors (EEG/EMG/IMU) with game-based neurorehabilitation for remote MS management.
• Holistic Digital Biomarker Generation: Unlike previous studies focusing on single modalities (e.g., just speech or just gait), BodyMirror fuses multiple data streams to create a comprehensive "digital twin" of neurological function.
• Privacy-Preserving AI: The implementation of Federated Learning in a clinical MS trial sets a precedent for decentralized data analysis, allowing AI model training without compromising patient privacy.
• Differentiation of Disease Subtypes: The study specifically targets both RRMS and SPMS (with a 60% SPMS focus), addressing the critical need for monitoring silent progression in advanced stages where traditional therapies often fail.
• Gamified Neurorehabilitation: It validates a "closed-loop" approach where assessment and treatment are merged into engaging games, potentially improving patient adherence compared to traditional therapy.

4. Results

• Status: As this document is a clinical trial protocol (preprint), no clinical results or efficacy data are yet available.
• Feasibility Data: The protocol cites preliminary feasibility testing with 15 participants showing:

  • 95% successful data capture rate.

  • High user adherence and engagement.
  • Successful validation of sensor signal quality against clinical standards in a home environment.
• Expected Outcomes: The trial aims to demonstrate that the intervention group will show:
  • Slower progression in EDSS scores compared to the control group.
  • Improved cognitive and motor performance metrics.
  • Earlier detection of disease progression via digital biomarkers compared to standard MRI/clinical visits.

5. Significance

• Clinical Impact: If successful, BodyMirror could shift MS management from episodic, hospital-based monitoring to continuous, remote, and personalized care. This enables earlier intervention for "silent progression," potentially slowing disability accumulation.
• Health Economics: By reducing the need for frequent hospital visits and enabling decentralized clinical trials, the technology could significantly lower the economic burden of MS care and drug development.
• Scientific Advancement: The study provides a robust framework for validating digital therapeutics (DTx) and establishing normative data for multimodal biosignals in neurodegenerative diseases.
• Patient Empowerment: The gamified approach empowers patients to actively participate in their rehabilitation, improving quality of life and adherence to treatment protocols.

In summary, the BodyMirror Clinical MS™ protocol outlines a rigorous, privacy-focused, and technologically advanced approach to solving the critical challenges of monitoring and treating Multiple Sclerosis, moving beyond traditional episodic care toward a continuous, data-driven, and patient-centric model.